 |
|
|
 |
|
|
|
 |
GreenPeptide is the drug discovery venture company
launched by Kurume University. Our strong connection to the University
makes it easier for us to gather the clinical data required to secure
approval for new technologies and new pharmaceutical agents, and
makes it possible for us to focus particular attention on the development
of pharmaceutical agents that show special promise.
At this stage, we are developing pharmaceutical agents based on the
accumulated results of basic and clinical research carried out at
Kurume University, however, it generally takes a long time for a
new agent to gain approval and enter the market.
Therefore, we have developed a business model in which we ask pharmaceutical-related
companies to fund development costs at each stage of the development
process, i.e. at the initial contract stage, at the phase I trial
stage, and at the phase II trial stage.
For this reason, we are currently negotiating joint development agreements
with several pharmaceutical-related companies at home and abroad.
|
 |
| Although the costs of clinical trials are
very high, in some cases the Company will use its own funds
to cover development costs until approval is gained from the
Ministry of Health, Labour and Welfare. |
 |
| As clinical trials at present are extremely
expensive, the Company will invite other companies to share
development costs until approval can be gained from the Ministry
of Health, Labour and Welfare. |
|
| We will market our products independently,
and/or jointly with companies that have their own sales and
distribution networks. |
We may grant exclusive sales rights or joint
marketing rights to other companies.
In this case the Company will aim to become a supplier. |
|
 |
| As clinical trials at present are extremely
expensive, the Company will invite other companies to share
development costs until approval can be gained from the Ministry
of Health, Labour and Welfare. |
|
| We will market our products independently,
and/or jointly with companies that have their own sales and
distribution networks. |
We may grant exclusive sales rights or joint
marketing rights to other companies.
In this case the Company will aim to become a supplier. |
|
 |
| In addition to exclusive marketing rights,
all rights to the pharmaceutical agent, including development
rights, are licensed to other companies. |
|
| In this case the company that has been licensed
by GreenPeptide assumes primary responsibility for the cost
of developing the pharmaceutical agent until approval is received
from the Ministry of Health, Labour and Welfare. |
|
| In this case, marketing will be conducted
independently by the company that has received the marketing
rights. |
| In this case, the licensed company may further
license-out its marketing rights to other companies and market
the products jointly. |
|
 |
| Although the costs of clinical trials are
very high, in some cases the Company will use its own funds
to cover development costs until approval is gained from the
Ministry of Health, Labour and Welfare. |
|
| In this case, when its pharmaceutical agents
are approved and the time comes to market its products, the
Company will establish its own independent sales network and
distribution chain. |
| We will market our products independently,
and/or jointly with companies that have their own sales and
distribution networks. |
We may grant exclusive sales rights or joint
marketing rights to other companies.
In this case the Company will aim to become a supplier. |
|
|
 |
|
|
|
|
